Document:

Exhibit 10.14

 

HELICOS BIOSCIENCES CORPORATION

 

Management Incentive Bonus Plan

 

1.                                       Purpose

 

This Management Incentive Bonus Plan (the “Incentive
Plan”) is intended to provide an incentive for superior work and to
motivate eligible executives of Helicos BioSciences Corporation (the “Company”)
and its subsidiaries toward even higher achievement and business results, to
tie their goals and interests to those of the Company and its stockholders and
to enable the Company to attract and retain highly qualified individuals. The
Incentive Plan is for the benefit of Covered Executives (as defined below) and does not govern the Company’s
base salary and long-term equity awards compensation practices.

 

2.                                       Covered
Executives

 

From time to time, the Compensation Committee of the
Board of Directors of the Company (the “Compensation Committee”) may select
certain key executives (the “Covered Executives”) to be eligible to
receive bonuses hereunder. A list of the Covered Executives (by title) under
this Incentive Plan for any given year is set forth on Appendix A. Other
individuals may become Covered Executives during a performance period
provided each such an individual is: (1) an employee of the Company; (2) recommended
for participation by the Chief Executive Officer; and (3) approved for
participation by the Compensation Committee.

 

3.                                       Administration

 

The Compensation Committee shall have the sole
discretion and authority to administer and interpret the Incentive Plan. The
responsibilities of the Compensation Committee and Chief Executive Officer
under the Incentive Plan shall be as follows:

 

•             Chief
Executive Officer Responsibilities:

•                  Recommend
to the Compensation Committee the Covered Executives
for Incentive Plan participation;

•                  Propose
performance measures, weightings, and performance levels for the Incentive
Plan, and changes thereto;

•                  Communicate
Incentive Plan parameters and mechanics to Covered Executives;

•                  Evaluate
actual performance against bonus measures and goals;

•                  Evaluate
individual performance of the Covered Executives (except the Chief Executive
Officer); and

•                  Develop
specific bonus recommendations for all Covered Executives
(except the Chief Executive Officer) and submit to the Compensation Committee
for review and approval.

 

 

•             Compensation
Committee Responsibilities:

•                  Approve
new Covered Executives;

•                  Review
and approve target bonus awards, including benchmarking to peer group companies;

•                  Review
and approve bonus measures, goals, and weightings;

•                  Certify
achievement of bonus measures;

•                  Evaluate
the Chief Executive Officer’s performance and determine and approve the Chief
Executive Officer’s bonus based on such evaluation; and

•                  Determine
the bonus for Covered Executives based upon the Chief Executive
Officer’s recommendations.

 

4.                                       Bonus
Determinations

 

(a)                                  A
Covered Executive may receive a bonus payment under the Incentive Plan
based upon the attainment of corporate performance targets approved by the
Compensation Committee that relate to financial, operational or strategic
metrics with respect to the Company or any of its subsidiaries (the “Corporate
Performance Goals”) and the individual performance of the Covered Executives
(as determined by the Chief Executive Officer for each Covered Executive other
than himself) and approved by the Compensation Committee. The Corporate Performance
Goals for any given performance period shall be attached hereto as Appendix
B. The Compensation Committee
reserves the right to modify the Corporate Performance Goals, the target bonus
amounts and the weighting of the bonus payment between corporate and individual
performance at any time during the course of the performance period in response
to changing business goals, needs and operations.

 

(b)                                 Except
as otherwise set forth in this Section 4 or with respect to individual
performance determinations:  (i) any
bonuses paid to Covered Executives under the Incentive Plan shall be based upon
objectively determinable bonus formulas that tie such bonuses to one or more
performance targets relating to the Corporate Performance Goals, (ii) bonus
formulas for Covered Executives shall be adopted in each performance period by
the Compensation Committee and (iii) no bonuses shall be paid to Covered
Executives unless and until the Compensation Committee makes a determination
with respect to the attainment of the performance objectives.

 

(c)                                  The
targeted bonus opportunity (measured as a percentage of salary) and weighting
between Corporate Performance Goals and individual performance measurement for
each Covered Executive is set forth on Appendix A hereto for each
performance period. The Company must
attain the minimum Corporate Performance Goals for any bonus payment to be made.
In the event that the minimum threshold for achievement of the Corporate
Performance Goals has not been attained then no Covered Executive shall be
eligible for the portion of the target bonus opportunity attributable to
individual performance as measured on Appendix B. Notwithstanding
anything contained herein to the contrary, the Company may adjust bonuses
payable under the Incentive Plan based on achievement of individual performance
goals or pay bonuses (including, without limitation, discretionary bonuses) to
Covered Executives under the Incentive Plan based upon such other terms and
conditions as the Compensation Committee may in its discretion determine.

 

2

 

(d)                                 A Covered Executive may be awarded
bonuses in excess of the targeted bonus opportunity as set forth on Appendix
B as a “Stretch” bonus amount if
(i) the Company exceeds the Corporate Performance Goals established by the
Compensation Committee and/or (ii) the Company achieves at least the
minimum Corporate Performance Goals established by the Compensation Committee
and the individual performance of such Covered Executive is measured as
outstanding. Notwithstanding the foregoing, the maximum bonus payable to
a Covered Executive under the Incentive Plan shall not exceed 200% of the
Covered Executive’s target bonus opportunity.

 

(e)                                  The
payment of a bonus to a Covered Executive with respect to a performance period
shall be conditioned upon the Covered Executive’s employment by the Company on
the last day of the performance period; provided, however, that the
Compensation Committee may make exceptions to this requirement, in its
sole discretion, including, without limitation, in the case of a Covered
Executive’s termination of employment, retirement, death or disability.

 

5.                                       Performance
Period and Timing of Payment

 

This
Incentive Plan will measure and reward performance on an annual basis (January 1
– December 31). The Corporate Performance Goals will be measured at
the end of each fiscal year after the Company’s financial reports have been
published. If the Corporate Performance Goals are met, payments will be made
within 30 days thereafter, but not later than March 15.

 

6.                                       Amendment
and Termination

 

The Company reserves the right to amend or terminate
the Incentive Plan at any time in its sole discretion.

 

7.                                       Miscellaneous

 

The bonus opportunity for individuals
who become Covered Executives during a performance period will be prorated
based on the number of full and partial months remaining in the performance
period at the time Incentive Plan participation is approved. In the case of a Covered Executive’s death, total disability or retirement
during the plan year, a prorated award may be granted in the sole
discretion of the Compensation Committee based on the full-year corporate
results and the level of achievement of individual goals anticipated had the Covered
Executive remained actively employed
for the entire year. The proration will be based on the number of months worked.
Payment to a deceased Covered Executive will be made to his/her estate.

 

Nothing contained in this document shall be deemed
to alter the relationship between the Company and a Covered Executive, or the contractual relationship between a Covered
Executive and the Company if there is a
written contract regarding such relationship. Furthermore, nothing contained in
this document shall be construed to constitute a contract of employment between
the Company and the Covered Executive. The Company and each of the Covered Executives continue to have the right to terminate the
employment or service relationship at any time for any reason, except as
provided in a written contract.

 

3

 

Appendix A

 

Fiscal 2007 Target Bonus Opportunity

 

	
  Position

  	
   

  	
  Target Bonus Opportunity*

  (as a percentage of base salary)

  	
   

  
	
  Chief Executive Officer

  	
   

  	
  30

  	
  %

  
	
  Chief Operating Officer

  	
   

  	
  30

  	
  %

  
	
  Chief Financial Officer

  	
   

  	
  30

  	
  %

  
	
  Executive Vice President Level

  	
   

  	
  30

  	
  %

  
	
  Senior Vice President Level

  	
   

  	
  30

  	
  %

  
	
  Vice President Level

  	
   

  	
  30

  	
  %

  
	
   

  	
   

  	
   

  	
   

  

 

* Target Bonus Opportunity shall be weighted two-thirds (66.7%) based
on achievement of Corporate Performance Goals (the “Corporate Bonus
Opportunity”) and one-third (33.3%) based on individual performance (the “Individual
Bonus Opportunity”).

 

 

Appendix B

 

Fiscal 2007 Corporate Performance Goals

 

	
   

  	
   

  	
  Number of HeliScope Systems Shipped in Fiscal
  2007

  	
   

  
	
  Annual
  Cash Burn for Fiscal 2007

  	
   

  	
  [Redacted]

  	
   

  	
  [Redacted]

  	
   

  	
  [Redacted]

  	
   

  	
  [Redacted]

  	
   

  	
  [Redacted]

  	
   

  	
  [Redacted]

  	
   

  
	
  Less
  than [Redacted]

  	
   

  	
  ––

  	
   

  	
  80

  	
  %

  	
  90

  	
  %

  	
  100

  	
  %

  	
  Stretch

  	
   

  	
  Stretch

  	
   

  
	
  Between [Redacted]

  	
   

  	
  ––

  	
   

  	
  70

  	
  %

  	
  80

  	
  %

  	
  90

  	
  %

  	
  100

  	
  %

  	
  Stretch

  	
   

  
	
  Between [Redacted]

  	
   

  	
  ––

  	
   

  	
  60

  	
  %

  	
  70

  	
  %

  	
  80

  	
  %

  	
  90

  	
  %

  	
  100

  	
  %

  
	
  More
  than [Redacted]

  	
   

  	
  ––

  	
   

  	
  ––

  	
   

  	
  ––

  	
   

  	
  ––

  	
   

  	
  ––

  	
   

  	
  ––

  	
   

  

 

If
a Covered Executive is eligible to receive a “Stretch” bonus, the amount shall
be determined in the discretion of the Compensation Committee based on the
amount by which the Corporate Performance Goals have been met and/or exceeded;
provided, however, that that the maximum bonus payable to a Covered
Executive based on achievement of the Corporate Performance Goals under the
Incentive Plan shall be 200% of the Covered Executive’s Corporate Bonus
Opportunity.

 

Individual Performance Thresholds

 

If
the minimum Corporate Performance Goals are achieved as set forth above (e.g.,
a 60% payout threshold), then a Covered Executive is eligible to receive his or
her Individual Bonus Opportunity based on the individual performance of the
Covered Executive as set forth below:

 

Between 0% and 200% of the Individual Bonus
Opportunity shall be payable depending upon whether a Covered Executive’s individual
performance is measured as needing improvement, meeting expectations, exceeding
expectations or outstanding.Exhibit 10.16

 

AMENDMENT TO

AMENDED AND RESTATED INVESTOR RIGHTS
AGREEMENT

 

This AMENDMENT AGREEMENT (this “Agreement”), dated as of this 7th day
of May, 2007, is hereby entered into by and among Helicos BioSciences
Corporation, a Delaware corporation (the “Company”) and the undersigned holders
of the Company’s Series A Convertible Preferred Stock (“Series A Investors”)
and the undersigned holders of Series B Convertible Preferred Stock (the “Series
B Investors”) (the Series A Investors and Series B Investors being referred to
collectively as the “Investors”). Capitalized terms used but not otherwise
defined herein shall have the respective meanings ascribed to them in that
certain Amended and Restated Investor Rights Agreement, dated as of March 1,
2006 (as amended and in effect, the “Investor Rights Agreement”).

 

WHEREAS, the Company and the Investors are parties to the Investor
Rights Agreement;

 

WHEREAS, the Company has filed with the Securities and Exchange
Commission of a Registration Statement on Form S-1 (as amended from time to
time, the “Registration Statement”) to effect a firmly underwritten, registered
initial public offering of common stock of the Company (the “IPO”);

 

WHEREAS, to facilitate and consummate the IPO, the Company and the
Investors desire amend the definition of Qualified Public Offering in Section 1
of the Investor Rights Agreement to include the IPO.

 

WHEREAS, pursuant to Section 15(d) of the Investor Rights Agreement,
the Company and Investors holding at least a majority in interest of the
Restricted Stock held by Investors have the power to amend the Investor Rights
Agreement (the “Requisite Parties”); and

 

WHEREAS, the Company and the Investors, constituting the Requisite
Parties, hereby consent to amend the Investor Rights Agreement as set forth
herein.

 

NOW THEREFORE, in consideration of the mutual promises and covenants
made herein and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties hereto hereby consent
to the following and covenant and agree as follows:

 

1.             Amended
Definition of Qualified Public Offering. Beginning on and after the
Effective Date (as defined below), the definition of Qualified Public Offering
in the Investor Rights Agreement shall be deleted and replaced in its entirety
by the following:

 

“Qualified Public Offering” shall mean an
underwritten public offering pursuant to an effective registration under the
Securities Act covering the offer and sale by the Company of its Common Stock on the New York Stock Exchange or The NASDAQ
Global Market in which the aggregate offering proceeds to the Company equal or
exceed $40 million (and, after August 31, 2007, $50 million) and the per share
offering price of at least $12.00 or such lower amount as may be determined by
the vote or written consent of at

 

 

least a two-thirds majority
of the members of the Company’s Board of Directors on or prior to August 31,
2007 (and, after August 31, 2007, $17.415) (after giving effect to the four and
one-half-for-one reverse stock split effected by the Company in May 2007 and
subject to appropriate adjustment by the Company’s Board of Directors in the
event of any subsequent stock split or similar event).

 

2.             Remaining
Provisions of Investor Rights Agreement. Except as provided herein, each of
the other provisions of the Investor Rights Agreement shall remain in full
force and effect. The parties hereto hereby confirm and agree that the
amendment or waiver provisions of the Investor Rights Agreement shall remain in
full force and effect and any amendment or waiver of any terms of the Investor
Rights Agreement (as modified hereby) shall be governed by, and be effect in
accordance with, the terms of the Investor Rights Agreement.

 

3.             Effective
Date. This Agreement shall be effective as of the date on which the Company’s
Third Amended and Restated Certificate of Incorporation is filed with the
Secretary of the State of Delaware in connection with the IPO (the “Effective
Date”).

 

4.             Miscellaneous.

 

(a)           This
Agreement shall be governed by Delaware law without regard to conflicts of law
principles.

 

(b)           This
Agreement may be executed in one or more counterparts (including via
facsimile), each of which shall be deemed an original but all of which together
shall constitute one and the same instrument.

 

(c)           This
Agreement (including any exhibit or schedule hereto) and the Investor Rights
Agreement constitute the full and entire understanding and agreement between
the parties hereto with respect to the subject matter hereof.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

2

 

Please indicate your acceptance of the foregoing by signing and
returning the enclosed counterpart of this Agreement, whereupon this Agreement
shall be a binding agreement between the Company and you.

 

	
   

  	
  Very truly yours,

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  HELICOS BIOSCIENCES CORPORATION

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/ Stanley N. Lapidus

  	
   

  
	
   

  	
  Name:

  	
  Stanley N. Lapidus

  
	
   

  	
  Title:

  	
  President

  
					

 

AMENDMENT TO INVESTOR RIGHTS AGREEMENT

 

 

AGREED TO AND ACCEPTED as of
the date first above written.

 

 

INVESTORS:

 

 

	
  /s/ Stanley N. Lapidus

  	
   

  	
   

  
	
  Stanley
  N. Lapidus

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  NEWCOGEN GROUP LLC;

  	
   

  
	
  NEWCOGEN EQUITY
  INVESTORS LLC;

  	
   

  
	
  NEWCOGEN PE LLC;

  	
   

  
	
  NEWCOGEN ÉLAN LLC;

  	
   

  
	
  ST NEWCOGEN LLC;

  	
   

  
	
  NEWCOGEN LONG REIGN
  HOLDING LLC

  	
   

  
	
   

  	
   

  
	
  Each by its Manager
  NewcoGen Group Inc.

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Noubar B. Afeyan

  	
   

  
	
   

  	
  Noubar B. Afeyan

  	
   

  
	
   

  	
  President

  	
   

  
	
   

  	
   

  
	
  APPLIED GENOMIC
  TECHNOLOGY CAPITAL FUND, L.P.;

  	
   

  
	
  AGTC ADVISORS FUND,
  L.P.

  	
   

  
	
   

  	
   

  
	
  Each by its General Partner, AGTC Partners, L.P.

  	
   

  
	
  By
  its General Partner, NewcoGen Group Inc.

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Noubar B. Afeyan

  	
   

  	
   

  
	
   

  	
  Noubar
  B. Afeyan

  	
   

  
	
   

  	
  President

  	
   

  
	
   

  	
   

  
	
  FLAGSHIP VENTURES FUND
  2004, L.P.

  	
   

  
	
   

  	
   

  
	
  By:

  	
  Flagship Ventures
  General Partner LLC,

  	
   

  
	
   

  	
  its General Partner

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Noubar B. Afeyan

  	
   

  	
   

  
	
  Name:

  	
  Noubar B. Afeyan

  	
   

  	
   

  
	
  Title:

  	
  President

  	
   

  	
   

  
								

 

 

	
  AGREED TO AND ACCEPTED
  as of the date first above written.

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  ATLAS VENTURE FUND V,
  L.P.

  	
   

  
	
  ATLAS VENTURE PARALLEL
  FUND V-A, C.V.

  	
   

  
	
  ATLAS VENTURE
  ENTREPRENEURS’ FUND V, L.P.

  	
   

  
	
   

  	
   

  
	
  By:  Atlas Venture Associates V, L.P.

  	
   

  
	
  their general partner

  	
   

  
	
  By:  Atlas Venture Associates V, Inc.

  	
   

  
	
  its general partner

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  /s/ Illegible

  	
   

  	
   

  
	
  Vice President

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  ATLAS VENTURE FUND VI,
  L.P.

  	
   

  
	
  ATLAS VENTURE
  ENTREPRENEURS’ FUND VI, L.P.

  	
   

  
	
   

  	
   

  
	
  By:  Atlas Venture Associates VI, L.P.

  	
   

  
	
  their general partner

  	
   

  
	
  By:  Atlas Venture Associates VI, Inc.

  	
   

  
	
  its general partner

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  /s/ Illegible

  	
   

  	
   

  
	
  Vice President

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  ATLAS VENTURE FUND VI
  GMBH & CO. KG

  	
   

  
	
   

  	
   

  
	
  By:  Atlas Venture Associates VI, L.P.

  	
   

  
	
  its managing limited
  partner

  	
   

  
	
  By:  Atlas Venture Associates VI, Inc.

  	
   

  
	
  its general partner

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  /s/ Illegible

  	
   

  	
   

  
	
  Vice President

  	
   

  
					

 

 

	
  AGREED TO AND ACCEPTED
  as of the date first above written.

  	
   

  
	
   

  	
   

  
	
  MPM BIOVENTURES III,
  L.P.

  	
   

  
	
   

  	
   

  
	
  By:  MPM BioVentures III GP, L.P., its General
  Partner

  	
   

  
	
  By:  MPM BioVentures III LLC, its General
  Partner

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Ansbert Gadicke

  	
   

  	
   

  
	
  Name:  Ansbert Gadicke

  	
   

  
	
  Title: Series A Member

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  MPM BIOVENTURES III-QP,
  L.P.

  	
   

  
	
   

  	
   

  
	
  By:  MPM BioVentures III GP, L.P., its General
  Partner

  	
   

  
	
  By:  MPM BioVentures III LLC, its General
  Partner

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Ansbert Gadicke

  	
   

  	
   

  
	
  Name: Ansbert Gadicke

  	
   

  
	
  Title: Series A Member

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  MPM BIOVENTURES III
  GMBH & CO. BETEILIGUNGS KG

  	
   

  
	
   

  	
   

  
	
  By:  MPM BioVentures III GP, L.P., in its
  capacity as the Managing Limited Partner

  	
   

  
	
  By:  MPM BioVentures III LLC, its General
  Partner

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Ansbert Gadicke

  	
   

  	
   

  
	
  Name: Ansbert Gadicke

  	
   

  
	
  Title: Series A Member

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  MPM BIOVENTURES III
  PARALLEL FUND, L.P.

  	
   

  
	
   

  	
   

  
	
  By:  MPM BioVentures III GP, L.P., its General
  Partner

  	
   

  
	
  By:  MPM BioVentures III LLC, its General
  Partner

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Ansbert Gadicke

  	
   

  	
   

  
	
  Name: Ansbert Gadicke

  	
   

  
	
  Title: Series A Member

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  MPM ASSET MANAGEMENT
  INVESTORS 2003 BVIII LLC

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ Ansbert Gadicke

  	
   

  	
   

  
	
  Name: Ansbert Gadicke

  	
   

  
	
  Title: Manager

  	
   

  
						

 

 

	
  AGREED TO AND ACCEPTED
  as of the date first above written.

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  HIGHLAND
  CAPITAL PARTNERS VI LIMITED PARTNERSHIP

  	
   

  
	
   

  	
   

  
	
  By:
  Highland Management Partners VI Limited Partnership, its General Partner

  	
   

  
	
  By:
  Highland Management Partners VI, Inc., its General Partner

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ ILLEGIBLE

  	
   

  	
   

  
	
   

  	
  Authorized
  Officer

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  HIGHLAND
  CAPITAL PARTNERS VI-B LIMITED PARTNERSHIP

  	
   

  
	
   

  	
   

  
	
  By:
  Highland Management Partners VI Limited Partnership, its General Partner

  	
   

  
	
  By:  Highland Management Partners VI, Inc., its
  General Partner

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ ILLEGIBLE

  	
   

  	
   

  
	
   

  	
  Authorized
  Officer

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  HIGHLAND
  ENTREPRENEURS’ FUND VI LIMITED PARTNERSHIP

  	
   

  
	
   

  	
   

  
	
  By:
  HEF VI Limited Partnership, its General Partner

  	
   

  
	
  By:  Highland Management Partners VI, Inc., its
  General Partner

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/ ILLEGIBLE

  	
   

  	
   

  
	
   

  	
  Authorized
  Officer

  	
   

  	
   

  

 

 

	
  AGREED TO AND ACCEPTED
  as of the date first above written.

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  VERSANT
  VENTURE CAPITAL II, L.P.

  	
   

  
	
   

  	
   

  
	
  By:   Versant
  Ventures II, LLC,

  	
   

  
	
  Its General Partner

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /S/ Brian G. Atwood

  	
   

  	
   

  
	
   

  	
  Brian
  G. Atwood

  	
   

  	
   

  
	
   

  	
  Managing
  Director

  	
   

  	
   

  
	
   

  	
   

  
	
  VERSANT
  SIDE FUND II, L.P.

  	
   

  
	
   

  	
   

  
	
  By:  Versant
  Ventures II, LLC,

  	
   

  
	
  Its
  General Partner

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /S/ Brian G. Atwood

  	
   

  	
   

  
	
   

  	
  Brian
  G. Atwood

  	
   

  	
   

  
	
   

  	
  Managing
  Director

  	
   

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  VERSANT
  AFFILIATES FUND II-A, L.P.

  	
   

  
	
   

  	
   

  
	
  By:  Versant
  Ventures II, LLC,

  	
   

  
	
  Its
  General Partner

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /S/ Brian G. Atwood

  	
   

  	
   

  
	
   

  	
  Brian
  G. Atwood

  	
   

  	
   

  
	
   

  	
  Managing
  Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]